A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

• Status: Completed
• Trial end date: 2010-09-24
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• adult patients 18-65 years of age;

• previously untreated indolent nonfollicular non-Hodgkin's lymphoma;

• active disease;

• >=3 involved sites.

Exclusion Criteria:

• typical chronic lymphocytic leukemia;

• other malignancies within 3 years before study, except basal or squamous cell skin cancer or cancer in situ of the cervix;

• systemic corticosteroid use for >1 month;

• significant cardiovascular disease;

• central nervous system involvement;

• hepatitis B or C virus infection, or HIV infection.